Physical activity and training in sarcoidosis: review and experience-based recommendations

Expert Review of Respiratory Medicine

Volumn 10, Issue 10, 2016, Pages 1057-1068

  Strookappe, Bert ^a,b,c   Saketkoo, Lesley Ann ^b,d   Elfferich, Marjon ^a,b   Holland, Anne ^e   De Vries, Jolanda ^b,f   Knevel, Ton ^a   Drent, Marjolein ^b,c,g  

^a GELDERSE VALLEI HOSPITAL   (Netherlands)

^b Ild Care Foundation Research Team   (Netherlands)

^c ST ANTONIUS HOSPITAL   (Netherlands)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e LA TROBE UNIVERSITY   (Australia)

^f TILBURG UNIVERSITY   (Netherlands)

^g MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Dyspnea; endurance; fatigue; muscle strength; physical training; pulmonary rehabilitation; quality of life; recommendations; sarcoidosis

Indexed keywords

CINAHL; CLINICAL FEATURE; ENDURANCE TRAINING; EVIDENCE BASED PRACTICE; HEALTH SURVEY; HUMAN; INTERSTITIAL LUNG DISEASE; MANAGED CARE; MEDICAL EXPERT; MEDICAL INFORMATION; MEDLINE; PERSONAL EXPERIENCE; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PULMONARY REHABILITATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SARCOIDOSIS; SYSTEMATIC REVIEW; EXERCISE;

EXERCISE; HUMANS; SARCOIDOSIS;

EID: 84988598553     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1080/17476348.2016.1227244     Document Type: Review

References (80)

1. A.E.Holland, C.J.Hill, I.Glaspole, et al. Predictors of benefit following pulmonary rehabilitation for interstitial lung disease. Respir Med. 2012;106:429–435.
2. A.E.Holland, K.Wadell, M.A.Spruit How to adapt the pulmonary rehabilitation programme to patients with chronic respiratory disease other than COPD. Eur Respir Rev. 2013;22:577–586.
3. M.A.Spruit, S.J.Singh, C.Garvey, et al. An official American Thoracic Society/European Respiratory Society statement:key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188:e13–64.
4. J.J.Swigris, K.K.Brown, B.J.Make, et al. Pulmonary rehabilitation in idiopathic pulmonary fibrosis:a call for continued investigation. Respir Med. 2008;102:1675–1680.
5. J.J.Swigris, D.L.Fairclough, M.Morrison, et al. Benefits of pulmonary rehabilitation in idiopathic pulmonary fibrosis. Respir Care. 2011;56:783–789.
6. B.K.Pedersen, B.Saltin. Exercise as medicine - evidence for prescribing exercise as therapy in 26 different chronic diseases. Scand J Med Sci Sports. 2015;25(Suppl 3):1–72.
7. D.Valeyre, A.Prasse, H.Nunes, et al. Sarcoidosis. Lancet. 2014;383:1155–1167.
8. M.A.Judson, M.Mack, J.L.Beaumont, et al. Validation and important differences for the sarcoidosis assessment tool. A new patient-reported outcome measure. Am J Respir Crit Care Med. 2015;191:786–795.
9. M.A.Judson. The clinical features of sarcoidosis:a comprehensive review. Clin Rev Allergy Immunol. 2015;49:63–78.
10. M.Drent, B.Strookappe, E.Hoitsma, et al. Consequences of sarcoidosis. Clin Chest Med. 2015;36:727–737.• This review focuses on the impact of sarcoidosis on patient’s lives.
11. R.G.Marcellis, A.F.Lenssen, M.D.Elfferich, et al. Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J. 2011;38:628–634.•• This study showed that exercise intolerance, muscle weakness, and fatigue are frequent problems in both fatigued and nonfatigued sarcoidosis patients. Fatigue was predicted neither by exercise capacity nor by muscle strength.
12. J.De Vries, M.Drent. Quality of life and health status in sarcoidosis:a review of the literature. Clin Chest Med. 2008;29:525–532.
13. M.A.Judson. Quality of life assessment in Sarcoidosis. Clin Chest Med. 2015;36:739–750.
14. A.S.Patel, R.J.Siegert, D.Creamer, et al. The development and validation of the King’s sarcoidosis questionnaire for the assessment of health status. Thorax. 2013;68:57–65.• This study presented the King’s Sarcoidosis Questionnaire, a brief, valid and easy to administer health status measure in sarcoidosis.
15. J.De Vries, R.M.Wirnsberger. Fatigue, quality of life and health status in sarcoidosis. Eur Respir Mon. 2005;32:92–104.
16. J.De Vries, M.Drent. Relationship between perceived stress and sarcoidosis in a Dutch patient population. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21:57–63.
17. M.Drent, R.Marcellis, A.Lenssen, et al. Association between physical functions and quality of life in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31:117–128.
18. M.A.Spruit, M.J.Thomeer, R.Gosselink, et al. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax. 2005;60:32–38.
19. M.Panagiotou, V.Polychronopoulos, C.Strange. Respiratory and lower limb muscle function in interstitial lung disease. Chron Respir Dis. 2016;13:162–172.• This article reviews the impact of exercise rehabilitation on the morphologic, metabolic, and functional muscle profile and outcomes in PAH. Ultimately, muscle dysfunction offers a potentially fruitful field for therapeutic interventions, as it seems partially reversible by exercise training.
20. M.Drent, E.E.Lower, J.De Vries. Sarcoidosis-associated fatigue. Eur Respir J. 2012;40:255–263.
21. P.Huppmann, B.Sczepanski, M.Boensch, et al. Effects of inpatient pulmonary rehabilitation in patients with interstitial lung disease. Eur Respir J. 2013;42:444–453.
22. R.G.Marcellis, M.A.F.Veeke, I.Mesters, et al. Does physical training reduce fatigue in sarcoidosis? Sarcoidosis Vasc Diffuse Lung Dis. 2015;32:53–62.
23. B.Strookappe, J.Swigris, J.De Vries, et al. Benefits of physical training in Sarcoidosis. Lung. 2015;193:701–708.• Study including largest sarcoidosis population so far, describing the benefit of physical training in sarcoidosis.
24. M.N.Karadalli, M.Bosnak-Guclu, B.Camcioglu, et al. Effects of inspiratory muscle training in subjects with sarcoidosis:a randomized controlled clinical trial. Respir Care. 2015;61:483–494.
25. J.P.Vandenbroucke, E.von Elm, D.G.Altman, et al. Strengthening the reporting of observational studies in epidemiology (STROBE):explanation and elaboration. Int J Surg. 2014;12:1500–1524.
26. K.F.Schulz, D.G.Altman, D.Moher. CONSORT 2010 statement:updated guidelines for reporting parallel group randomised trials. PLoS Med. 2010;7:e1000251.
27. A.P.Verhagen, H.C.de Vet, R.A.de Bie, et al. The Delphi list:a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol. 1998;51:1235–1241.
28. E.Roddy, W.Zhang, M.Doherty, et al. Evidence-based clinical guidelines:a new system to better determine true strength of recommendation. J Eval Clin Pract. 2006;12:347–352.
29. B.Strookappe, M.Elfferich, J.Swigris, et al. Benefits of physical training in patients with idiopathic or end-stage sarcoidosis-related pulmonary fibrosis:a pilot study. Sarcoidosis Vasc Diffuse Lung Dis. 2015;32:43–52.
30. R.P.Baughman, M.Drent, D.A.Culver, et al. Endpoints for clinical trials of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29:90–98.
31. M.A.Judson, R.P.Baughman, U.Costabel, et al. Efficacy of infliximab in extrapulmonary sarcoidosis:results from a randomised trial. Eur Respir J. 2008;31:1189–1196.
32. M.A.Judson, U.Costabel, M.Drent, et al. The WASOG sarcoidosis organ assessment instrument:an update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31:19–27.
33. I.M.Lee, E.J.Shiroma, F.Lobelo, et al. Effect of physical inactivity on major non-communicable diseases worldwide:an analysis of burden of disease and life expectancy. Lancet. 2012;380:219–229.
34. D.Ding, K.D.Lawson, T.L.Kolbe-Alexander, et al. The economic burden of physical inactivity:a global analysis of major non-communicable diseases. Lancet. 2016; [Epub ahead of print]. DOI:10.1016/S0140-6736(16)30383-X
35. M.Drent. Sarcoidosis:benefits of a multidisciplinary approach. Eur J Intern Med. 2003;14:217–220.
36. I.H.Korenromp, C.J.Heijnen, O.J.Vogels, et al. Characterization of chronic fatigue in patients with sarcoidosis in clinical remission. Chest. 2011;140:441–447.
37. H.J.Michielsen, T.Peros-Golubicic, M.Drent, et al. Relationship between symptoms and quality of life in a sarcoidosis population. Respiration. 2007;74:401–405.
38. J.De Vries, S.Rothkrantz-Kos, M.P.van Dieijen-Visser, et al. The relationship between fatigue and clinical parameters in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21:127–136.
39. S.De Boer, J.Kolbe, M.L.Wilsher. The relationships among dyspnoea, health-related quality of life and psychological factors in sarcoidosis. Respirology. 2014;19:1019–1024.
40. R.M.Wirnsberger, J.De Vries, T.L.Jansen, et al. Impairment of quality of life:rheumatoid arthritis versus sarcoidosis. Neth J Med. 1999;54:86–95.
41. A.Bosse-Henck, H.Wirtz, A.Hinz. Subjective sleep quality in sarcoidosis. Sleep Med. 2015;16:570–576.
42. J.Verbraecken, E.Hoitsma, C.P.van der Grinten, et al. Sleep disturbances associated with periodic leg movements in chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21:137–146.
43. R.P.Baughman, P.J.Engel, S.Nathan. Pulmonary hypertension in sarcoidosis. Clin Chest Med. 2015;36:703–714.
44. B.Rp, B.K.Sparkman, E.E.Lower. Six-minute walk test and health status assessment in sarcoidosis. Chest. 2007;132:207–213.
45. R.G.Marcellis, A.F.Lenssen, J.de Vries, et al. Reduced muscle strength, exercise intolerance and disabling symptoms in sarcoidosis. Curr Opin Pulm Med. 2013;19:524–530.
46. D.Jastrzebski, D.Ziora, M.Lubecki, et al. Fatigue in sarcoidosis and exercise tolerance, dyspnea, and quality of life. Adv Exp Med Biol. 2015;833:31–36.
47. A.Hinz, E.Brähler, R.Möde, et al. Anxiety and depression in sarcoidosis:the influence of age, gender, affected organs, concomitant diseases and dyspnea. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29:139–146.• This study found that dyspnea is an important symptom in the prediction of anxiety and depression.
48. H.J.Kabitz, F.Lang, S.Walterspacher, et al. Impact of impaired inspiratory muscle strength on dyspnea and walking capacity in sarcoidosis. Chest. 2006;130:1496–1502.
49. M.J.Van Manen, M.Wapenaar, B.Strookappe, et al. Validation of the King’s Sarcoidosis Questionnaire (KSQ) in a Dutch sarcoidosis population. Sarcoidosis Vasc Diffuse Lung Dis. 2016;33:75–82.
50. R.M.Wirnsberger, J.de Vries, M.H.Breteler, et al. Evaluation of quality of life in sarcoidosis patients. Respir Med. 1998;92:750–756.
51. R.P.Baughman, A.S.Teirstein, M.A.Judson, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164:1885–1889.
52. A.E.Holland, L.M.Dowman, C.J.Hill. Principles of rehabilitation and reactivation:interstitial lung disease, sarcoidosis and rheumatoid disease with respiratory involvement. Respiration. 2015;89:89–99.•• Interesting review about rehabilitation in ILD.
53. R.M.Wirnsberger, M.Drent, N.Hekelaar, et al. Relationship between respiratory muscle function and quality of life in sarcoidosis. Eur Respir J. 1997;10:1450–1455.
54. A.Baydur, M.Alsalek, S.G.Louie, et al. Respiratory muscle strength, lung function, and dyspnea in patients with sarcoidosis. Chest. 2001;120:102–108.
55. R.W.Bohannon. Test-retest reliability of hand-held dynamometry during a single session of strength assessment. Phys Ther. 1986;66:206–209.
56. J.P.Cremers, M.Drent, M.D.Elfferich, et al. Body composition profiling in a Dutch sarcoidosis population. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30:289–299.
57. J.P.Cremers, M.J.Van Kroonenburgh, R.L.Mostard, et al. Extent of disease activity assessed by 18F-FDG PET/CT in a Dutch sarcoidosis population. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31:37–45.
58. A.Silverstein, L.E.Siltzbach. Muscle involvement in sarcoidosis. Asymptomatic, myositis, and myopathy. Arch Neurol. 1969;21:235–241.
59. R.M.Wirnsberger, J.de Vries, E.F.Wouters, et al. Clinical presentation of sarcoidosis in The Netherlands an epidemiological study. Neth J Med. 1998;53:53–60.
60. U.Costabel. Skeletal muscle weakness, fatigue and sarcoidosis. Thorax. 2005;60:1–2.
61. S.Walterspacher, D.Schlager, D.J.Walker, et al. Respiratory muscle function in interstitial lung disease. Eur Respir J. 2013;42:211–219.
62. E.Hoitsma, M.Marziniak, C.G.Faber, et al. Small fibre neuropathy in sarcoidosis. Lancet. 2002;359:2085–2086.
63. M.D.Elfferich, P.J.Nelemans, R.W.Ponds, et al. Everyday cognitive failure in sarcoidosis:the prevalence and the effect of anti-TNF-alpha treatment. Respiration. 2010;80:212–219.
64. E.Hoitsma, J.De Vries, M.Drent. The small fiber neuropathy screening list:construction and cross-validation in sarcoidosis. Respir Med. 2011;105:95–100.
65. M.A.Judson. Small fiber neuropathy in sarcoidosis:something beneath the surface. Respir Med. 2011;105:1–2.
66. E.Hoitsma, M.Drent, O.P.Sharma. A pragmatic approach to diagnosing and treating neurosarcoidosis in the 21st century. Curr Opin Pulm Med. 2010;16:472–479.
67. J.Tavee, D.Culver. Sarcoidosis and small-fiber neuropathy. Curr Pain Headache Rep. 2011;15:201–206.
68. R.P.Baughman, H.Nunes. Therapy for sarcoidosis:evidence-based recommendations. Expert Rev Clin Immunol. 2012;8:95–103.
69. M.D.Elfferich, J.De Vries, M.Drent. Type D or ‘distressed’ personality in sarcoidosis and idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28:65–71.
70. L.N.Saligan. The relationship between physical activity, functional performance and fatigue in sarcoidosis. J Clin Nurs. 2014;23:2376–2378.
71. H.J.Michielsen, M.Drent, T.Peros-Golubicic, et al. Fatigue is associated with quality of life in sarcoidosis patients. Chest. 2006;130:989–994.
72. P.Brancaleone, T.Perez, S.Robin, et al. Clinical impact of inspiratory muscle impairment in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21:219–227.
73. C.J.Ryerson, C.Cayou, F.Topp, et al. Pulmonary rehabilitation improves long-term outcomes in interstitial lung disease:a prospective cohort study. Respir Med. 2014;108:203–210.
74. M.A.Spruit, E.F.M.Wouters, R.Gosselink. Rehabilitation programmes in sarcoidosis:a multidisciplinary approach. Eur Respir Mon. 2005;32:316–326.
75. A.E.Holland, C.J.Hill, M.Conron, et al. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax. 2008;63:549–554.
76. M.Panagiotou, A.J.Peacock, M.K.Johnson. Respiratory and limb muscle dysfunction in pulmonary arterial hypertension:a role for exercise training? Pulm Circ. 2015;5:424–434.
77. H.Hebestreit, S.Kriemler, T.Radtke. Exercise for all cystic fibrosis patients:is the evidence strengthening? Curr Opin Pulm Med. 2015;21:591–595.
78. A.W.Boots, M.Drent, V.C.de Boer, et al. Quercetin reduces markers of oxidative stress and inflammation in sarcoidosis. Clin Nutr. 2011;30:506–512.
79. B.Rammaert, S.Leroy, B.Cavestri, et al. Home-based pulmonary rehabilitation in idiopathic pulmonary fibrosis. Rev Mal Respir. 2011;28:e52–57.
80. H.Lingner, A.Grosshennig, K.Flunkert, et al. ProKaSaRe study protocol:a prospective multicenter study of pulmonary rehabilitation of patients with sarcoidosis. JMIR Res Protoc. 2015;4:e134.